Interim phase II results from the COCOON trial suggest a 50% reduction in dermatologic toxicity with proactive skincare for patients receiving frontline therapy for EGFR-mutant non-small cell lung cancer. The interim data were reported in association with the trial’s ongoing evaluation. The trial’s approach matters because skin toxicities can force dose modifications and worsen quality of life, creating real downstream effects on adherence and outcomes in EGFR-driven regimens. By targeting preventable toxicity rather than only treating it after onset, COCOON reframes supportive care as an evidence-backed component of oncology delivery. Clinicians and sponsors will look for confirmatory readouts, how the intervention performs across severity grades, and whether proactive pathways can be standardized across treatment centers.